Publications

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Salas-Benito, D. et al.

Author Empty

Cell Therapy

Welsh, R. A. et al.

The Journal of Immumnology

Author Empty

Cell Therapy

Deng, T. et al.

Author Empty

Cell Therapy

Huerta-Yepez, S. et al.

BMJ Oncology

Author Empty

Cell Therapy

Maciocia, N. et al.

Science Translational Medicine

Author Empty

Cell Therapy

Zhang, H. et al.

Science Translational Medicine

Author Empty

Cell Therapy

Greco, B. et al.

Science Translational Medicine

Author Empty

Cell Therapy

Tual, M. et al.

Author Empty

Cell Therapy

Ma, K. et al.

Advanced Science

Author Empty

Cell Engagers

Benton, A. et al.

Author Empty

Cell Therapy

Navin, I. et al.

Cancer Immunology Research

Author Empty

Cell Therapy

Rodríguez-Lobato, L. G. et al.

Cancer Immunology Research

Author Empty

Cell Therapy

Wang, S. et al.

Clininical Cancer Res.

Author Empty

Cell Therapy

Barisa, M. et al.

Nature Communications

Author Empty

Cell Therapy

Zhu, Q. et al.

Cellular & Molecular Immunology

Author Empty

Cell Therapy

Barisa, M. et al.

Author Empty

Cell Therapy

O'Sullivan, A. et al.

Molecular Therapy

Author Empty

Cell Therapy

Somes, L. K. et al.

Molecular Therapy

Author Empty

Cell Therapy

Chaturantabut, S. et al.

J. Clin. Investigation

Author Empty

Antibody Therapy

Wang, Y. et al.

STAR Protocols

Author Empty

Cell Therapy

Boucher, J. C. et al.

Molecular Therapy Oncology

Author Empty

Cell Engagers

Carr, A. et al.

Biological Chemistry

Author Empty

Cell Therapy

Kamsma, D. et al.

Cell Reports

Author Empty

Cell Engagers

de Larrea, C. F. et al.

Blood Cancer Discovery

Author Empty

Cell Therapy

Katsarou, A. et al.

Science Translational Medicine

Author Empty

Cell Therapy

Balneger, N. et al.

Cell. Mol. Life Sci.

Author Empty

Antibody Therapy

Larson, R. C. et al.

Author Empty

Cell Therapy

Halim, L. et al.

Front. Immunol.

Author Empty

Cell Therapy

Leick, M. B. et al.

Author Empty

Cell Therapy

Li, Y. et al.

Nature Medicine

Author Empty

Cell Therapy

Perriello, V. M. et al.

Author Empty

Cell Therapy

Wang, Y. et al.

Author Empty

Cell Engagers

Patel, R. P. et al.

Science Immunology

Author Empty

Cell Therapy

Chockley, P. J. et al.

Nature Biotech

Author Empty

Cell Therapy

Lee, L. et al.

Author Empty

Cell Therapy

Sugiyarto, G. et al.

Author Empty

Antibody Therapy

Uhl, L. F. K et al.

Nature Communications

Author Empty

Antibody Therapy

Zhang, Y. et al.

Molecular Cancer

Author Empty

Cell Therapy

Bouti, P. et al.

Int. J. Mol. Science

Author Empty

Antibody Therapy

Wehrli, M. et al.

Clininical Cancer Res.

Author Empty

Cell Therapy

Wang, Y. et al.

Molecular Cancer

Author Empty

Cell Therapy

Grab, A. L. et al.

Author Empty

Cell Engagers

Arellano-Ballestero, H. et al.

Author Empty

Cell Therapy

Wang, Y. et al.

Cell Reports Medicine

Author Empty

Cell Therapy

O’Connell, R. P. et al.

Author Empty

Cell Engagers

Guruprasad, P. et al.

Nature Immunology

Author Empty

Cell Therapy

Bang, I. et al.

Nature Chemical Biology

Author Empty

Cell Engagers

Barden, M. et al.

Author Empty

Cell Therapy

Gad, Z. A. et al.

Science Advances

Author Empty

Cell Therapy

Bachiller, M. et al.

Molecular Therapy

Author Empty

Cell Therapy

Huang, D. et al.

Cell Reports

Author Empty

Antibody Therapy

Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time

Loss of the Class II Accessory Molecule HLA-DO leads to altered TCR avidity

CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo

Supercharged NK cells, unlike primary activated NK cells, effectively target ovarian cancer cells irrespective of MHC-class I expression

Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia

OX40Рheparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice

Systemic delivery of cadherin 17-specific CAR T cells allows effective and safe targeting of colorectal cancer liver metastases

MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence

An engineered soluble single-chain TCR engager for KRAS-G12V specific tumor immunotherapy

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy

TIGIT affects CAR NK cell effector function in the solid tumor microenvironment by modulating immune synapse strength

Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

IND-Enabling Studies for a TCR-T targeting a pancreatic cancer G12V KRAS mutation

Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function

CD2 augmentation enhances CAR-T-cell ef cacy via immunological synapse remodeling and T-cell exhaustion mitigation

Functional Avidity of Anti-B7H3 CAR T Constructs Predicts Antigen Density Threshold for Triggering Effector Function

Increased Functional Potency of Multi-Edited CAR T Cells Manufactured by a Non-Viral Transfection System

ZP4: A Novel Target for CAR T Cell Therapy in Triple Negative Breast Cancer

Identification of potent biparatopic antibodies targeting FGFR2 fusion driven cholangiocarcinoma

Protocol to measure cell avidity between cord blood-derived NK cells and leukemia cell line KG-1a

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia

Advances in preclinical TCR characterization: leveraging cell avidity to identify functional TCRs

Single-Cell Acoustic Force Spectroscopy: Resolving Kinetics and Strength of T Cell Adhesion to Fibronectin

Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma

Dual targeting with a CAR and a chimeric costimulatory receptor (CCR) enhances T cell sensitivity of tumor antigen recognition and persistence

Sialic acid blockade in BDMCs enhances CD8+ T cell responses by facilitating high avidity DC-T cell interactions

CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

Engineering of an avidity-optimized CD19-specific parallel chimeric antigen receptor that delivers dual CD28 and 4-1BB co-stimulation

Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia

KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape

IL3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML

Acoustic force-based cell–matrix avidity measurement in high throughput

CD5 deletion enhances the antitumor activity of adoptive T cell therapies

Synapse-tuned CARs enhance immune cell anti-tumor activity

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

Interferon-γ couples CD8+ T cell avidity and differentiation during infection

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity

Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma

Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects

Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma

Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy

Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia

Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma

The BTLA-HVEM axis restricts CAR T cell efficacy in cancer

Selective targeting of oncogenic hotspotmutations of the HER2 extracellular domain

Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function

Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells

ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma

TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens